TriMix DC

Drug Profile

TriMix DC

Alternative Names: TriMixDC

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator eTheRNA Immunotherapies
  • Developer Vrije Universiteit Brussel
  • Class Cancer vaccines; Cell therapies; Immunotherapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Malignant melanoma; Multiple myeloma

Most Recent Events

  • 27 Jul 2017 Vrije Universiteit Brussel has patent protection for TriMiX technology in USA and Europe
  • 12 Jul 2017 TriMix-DC is available for licensing as of 12 Jul 2017. http://www.etherna.be (eTheRNA website, July 2017)
  • 12 Jul 2017 Suspended - Phase-II for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Belgium (Intradermal) (IV) (eTheRNA website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top